Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NDRA vs PSNL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PSNL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)
PSNL Overall Winner
6-Pillar Tally: NDRA 1 – 4 PSNL (1 Tie)
Matrix Metrics: NDRA 3 – 5 PSNL
As of Nov 16, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas PSNL carries 33.0/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin).
- Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PSNL 33.0/100 SELL), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. 0.0% operating margin) and revenue trajectory (+76.6% vs. +0.0% YoY).
- Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile PSNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NDRA vs PSNL
NDRA
ENDRA Life Sciences Inc. Common Stock
$4.42
+0.23% 1D
Market Cap
$6.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.71β · 48% Vol
Unified Composite Score
44.7
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
PSNL
Head-to-Head Winner
Personalis, Inc. Common Stock
$14.80
-5.79% 1D
Market Cap
$1.7B
TTM Revenue
$81M
Forward P/E
N/M
Beta / 30D Vol
1.86β · 21% Vol
Unified Composite Score
33.0
SELL
Tech 9.0
Fund 48.0
Flow 58.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NDRA 1 – 4 PSNL)
1. Valuation Multiples
PSNL
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
20.3x
2. Growth & Scale
PSNL
Revenue Growth (YoY)
+0.0%
+76.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$81M
Market Cap
$6.6M
$1.7B
3. Profitability & Quality
NDRA
Gross Margin
N/A
16.7%
Operating Margin
0.0%
-156.7%
Net Profit Margin
0.0%
-147.7%
Return on Equity (ROE)
-152.0%
-62.1%
4. Balance Sheet & Cash Flow
PSNL
Cash Generation (TTM)
-$8.0M
-$108M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$104,744 Net Debt (0.26x D/E)
$61M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PSNL
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
35.2% (2nd %ile)
Put/Call OI Skew
N/A
0.02x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NDRA (3) vs PSNL (5)| Institutional Metric | NDRA | PSNL | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.6M | $1.7B | PSNL | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +76.6% | PSNL | |
| Operating Margin (TTM) | 0.0% | -156.7% | NDRA | |
| Net Profit Margin | 0.0% | -147.7% | NDRA | |
| Return on Equity (ROE) | -152.0% | -62.1% | PSNL | |
| 52-Week Range Position | 37% ($3–$7) | 71% ($5–$19) | PSNL | |
| Beta / 30D Volatility | 0.71β · 48% Vol | 1.86β · 21% Vol | PSNL | |
| Unified Institutional Score | 44.7 / 100 (HOLD) | 33.0 / 100 (SELL) | NDRA | |
| Trailing 12M Revenue (USD) | N/A | $81M | Scale | |
| Gross Profit Margin (TTM) | N/A | 16.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 20.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.0M ($104,744 Net Debt (0.26x D/E)) | -$108M ($61M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PSNL +1.32 pp
3M Horizon
PSNL +8.4 pp
6M Horizon
PSNL +138.54 pp
1Y Horizon
PSNL +127.46 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NDRA Revenue | PSNL Revenue | NDRA Op. Margin | PSNL Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $40M | -146080.5% | -36.5% | PSNL |
| FY2019 | N/A | $70M | N/A | -34.4% | PSNL |
| FY2020 | N/A | $80M | N/A | -53.6% | PSNL |
| FY2021 | N/A | $90M | N/A | -76.4% | PSNL |
| FY2022 | N/A | $70M | N/A | -177.6% | PSNL |
| FY2023 | N/A | $70M | N/A | -149.6% | PSNL |
| FY2024 | N/A | $80M | N/A | -80.7% | PSNL |
| FY2025 | N/A | $70M | N/A | -126.4% | PSNL |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NDRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PSNL
CONSOLIDATION
Current IV
35.2%
IV Percentile
2nd %ile
Put/Call OI Skew
0.02x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact PSNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NDRA Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PSNL Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ NDRA vs PSNL Key Questions & Quantitative Answers
As of Nov 16, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas PSNL carries 33.0/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PSNL 33.0/100 SELL), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. 0.0% operating margin) and revenue trajectory (+76.6% vs. +0.0% YoY). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile PSNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PSNL leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PSNL at +76.6% YoY revenue growth and +0.0% YoY earnings growth on $81M TTM revenue (16.7% gross margin, -156.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDRA cumulative revenue shifted N/A while PSNL shifted +75.0%. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSNL.
PSNL screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PSNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 20.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus PSNL (-62.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, PSNL carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.86β · 21% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PSNL vs NDRA · Reverse Pair
PSNL vs CDNA
· Sector Peer
PSNL vs TWST
· Sector Peer
PSNL vs VCYT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking